Dawn ME Bowdish

6

Articles

1

Comment
Researchers found a surprising twist in a study of Omicron infection in older adults. The new information highlights the importance of COVID-19 vaccine booster shots. (Shutterstock)

COVID‑19 vaccine boosters are the best defence: Older adults shouldn’t rely on previous infection for immunity

Dawn ME Bowdish, McMaster University and Andrew Costa, McMaster University

We still have much to learn about many aspects of COVID-19 — including its lingering health effects and the mechanics of its endless mutations — but we do know one thing: we can’t let our guard down.
COVID-19 is still with us, and is still causing serious illness and death. However, it is disproportionately affecting older people. THE CANADIAN PRESS/Chris Young

Ageism and the pandemic: How Canada continues to let older adults suffer and die from COVID‑19

Dawn ME Bowdish, McMaster University

COVID-19 is the third-leading cause of death in Canada, but it’s older people who are dying. That we accept this and carry on as if the pandemic is over reveals our ageism: We don’t value older people.
With the holiday season approaching, people wait to receive a COVID-19 vaccination in Montréal as the pandemic continues in Canada and around the world. THE CANADIAN PRESS/Graham Hughes

Answers from COVID experts: How do you talk to family members who aren’t vaccinated? How can the vaccines be safe if they were developed so quickly? Is natural immunity better than being vaccinated?

Scott White, The Conversation

A panel of experts answer questions about vaccines, omicron and other COVID-related issues in a discussion with The Conversation.
While people in the wealthy West have had preferred access to multiple rounds of vaccines, vast numbers of people, especially in Africa and on the Indian subcontinent, haven’t received a single dose. (Pixabay/Canva)

COVID‑19 vaccine inequity allowed Omicron to emerge

Dawn ME Bowdish, McMaster University and Chandrima Chakraborty, McMaster University

In places with low vaccination rates, COVID-19 has the chance to linger, and variants develop and travel. Without global vaccine equity, this entirely predictable pattern will repeat itself.
A healthcare worker holds up a vial of the AstraZeneca vaccine at a COVID-19 vaccination clinic in Montréal, on March 18. THE CANADIAN PRESS/Paul Chiasson 

Second dose of AstraZeneca COVID‑19 vaccine: FAQs about blood clots, safety, risks and symptoms

Dawn ME Bowdish, McMaster University and Ishac Nazy, McMaster University

Answers to key questions about rare blood clots linked to AstraZeneca’s COVID-19 vaccine, including risks, symptoms and whether people who have had one AstraZeneca shot should have a second.

Contact Dawn for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision